JMDC Valuation

Is 4483 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 4483 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 4483 (¥4246) is trading above our estimate of fair value (¥2586.9)

Significantly Below Fair Value: 4483 is trading above our estimate of fair value.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 4483?

Key metric: As 4483 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 4483. This is calculated by dividing 4483's market cap by their current earnings.
What is 4483's PE Ratio?
PE Ratio67.1x
EarningsJP¥4.13b
Market CapJP¥277.47b

Price to Earnings Ratio vs Peers

How does 4483's PE Ratio compare to its peers?

The above table shows the PE ratio for 4483 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average28.2x
4480 Medley
52.4x31.7%JP¥142.1b
24.9x12.2%JP¥976.1b
3733 Software Service
12.4x9.1%JP¥70.8b
4820 EM Systems
22.9x8.9%JP¥49.4b
4483 JMDC
67.1x24.9%JP¥277.5b

Price-To-Earnings vs Peers: 4483 is expensive based on its Price-To-Earnings Ratio (67.1x) compared to the peer average (28.2x).


Price to Earnings Ratio vs Industry

How does 4483's PE Ratio compare vs other companies in the Asian Healthcare Services Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
4483 67.1xIndustry Avg. 23.9xNo. of Companies5PE020406080100+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 4483 is expensive based on its Price-To-Earnings Ratio (67.1x) compared to the Asian Healthcare Services industry average (23.9x).


Price to Earnings Ratio vs Fair Ratio

What is 4483's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

4483 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio67.1x
Fair PE Ratio30.9x

Price-To-Earnings vs Fair Ratio: 4483 is expensive based on its Price-To-Earnings Ratio (67.1x) compared to the estimated Fair Price-To-Earnings Ratio (30.9x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 4483 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentJP¥4,246.00
JP¥5,545.45
+30.6%
17.6%JP¥7,000.00JP¥3,900.00n/a11
Nov ’25JP¥4,227.00
JP¥5,473.64
+29.5%
18.9%JP¥7,000.00JP¥3,900.00n/a11
Oct ’25JP¥4,698.00
JP¥5,473.64
+16.5%
18.9%JP¥7,000.00JP¥3,900.00n/a11
Sep ’25JP¥4,399.00
JP¥5,237.27
+19.1%
22.1%JP¥7,000.00JP¥3,600.00n/a11
Aug ’25JP¥3,211.00
JP¥4,843.00
+50.8%
27.9%JP¥7,000.00JP¥3,330.00n/a10
Jul ’25JP¥3,182.00
JP¥4,820.00
+51.5%
30.4%JP¥7,000.00JP¥3,330.00n/a9
Jun ’25JP¥2,739.50
JP¥4,938.00
+80.3%
29.0%JP¥7,000.00JP¥3,330.00n/a10
May ’25JP¥3,229.00
JP¥5,400.00
+67.2%
22.0%JP¥7,000.00JP¥3,650.00n/a10
Apr ’25JP¥3,580.00
JP¥5,840.00
+63.1%
25.0%JP¥9,100.00JP¥3,650.00n/a10
Mar ’25JP¥3,805.00
JP¥5,915.00
+55.5%
25.0%JP¥9,100.00JP¥3,650.00n/a10
Feb ’25JP¥3,850.00
JP¥6,206.00
+61.2%
24.8%JP¥10,060.00JP¥4,500.00n/a10
Jan ’25JP¥4,263.00
JP¥6,266.00
+47.0%
23.6%JP¥10,060.00JP¥4,670.00n/a10
Dec ’24JP¥4,271.00
JP¥6,396.00
+49.8%
23.3%JP¥10,060.00JP¥4,670.00n/a10
Nov ’24JP¥4,366.00
JP¥6,584.00
+50.8%
24.7%JP¥10,500.00JP¥4,810.00JP¥4,227.0010
Oct ’24JP¥5,439.00
JP¥6,817.50
+25.3%
25.1%JP¥10,500.00JP¥4,810.00JP¥4,698.008
Sep ’24JP¥4,368.00
JP¥6,732.22
+54.1%
26.7%JP¥10,500.00JP¥4,810.00JP¥4,399.009
Aug ’24JP¥5,400.00
JP¥7,111.11
+31.7%
21.1%JP¥10,400.00JP¥5,300.00JP¥3,211.009
Jul ’24JP¥5,704.00
JP¥7,033.33
+23.3%
22.3%JP¥10,400.00JP¥5,300.00JP¥3,182.009
Jun ’24JP¥5,600.00
JP¥6,800.00
+21.4%
22.0%JP¥9,600.00JP¥5,100.00JP¥2,739.509
May ’24JP¥4,725.00
JP¥6,775.00
+43.4%
24.5%JP¥9,500.00JP¥4,700.00JP¥3,229.008
Apr ’24JP¥4,550.00
JP¥6,742.86
+48.2%
26.3%JP¥9,500.00JP¥4,700.00JP¥3,580.007
Mar ’24JP¥4,210.00
JP¥6,711.43
+59.4%
26.8%JP¥9,500.00JP¥4,700.00JP¥3,805.007
Feb ’24JP¥4,290.00
JP¥6,757.14
+57.5%
26.8%JP¥9,500.00JP¥4,300.00JP¥3,850.007
Jan ’24JP¥3,780.00
JP¥7,121.43
+88.4%
25.5%JP¥10,000.00JP¥4,950.00JP¥4,263.007
Dec ’23JP¥5,190.00
JP¥7,700.00
+48.4%
23.5%JP¥10,000.00JP¥5,400.00JP¥4,271.006
Nov ’23JP¥5,210.00
JP¥7,816.67
+50.0%
24.6%JP¥10,600.00JP¥5,500.00JP¥4,366.006

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies